Archives

by in
Entry Author Date Location
Big Data Is BS in Healthcare. When Will It Become Real? 04/15/13 National
Biogen Idec Wins FDA Approval For Oral Multiple Sclerosis Drug 03/27/13 Boston
Prothena of South San Francisco Gets Head Start as Elan Spinoff 01/09/13 San Francisco
Seattle Genetics Sees Case of PML, Causing Market Twitch 12/01/11 Seattle
Immune Design, Developer of New Vaccines, Adds Former Elan President as New CEO 04/27/11 Seattle
Biogen Shares Jump on Good News on Revenue, Oral MS Drug 04/21/11 Boston
Biogen Idec Passes Pivotal Trial With Oral MS Drug; Shares Climb 04/11/11 Boston
FDA Wants More Data on Merck KGaA’s MS Pill As Biogen Develops Rival Therapy 03/02/11 Boston
Report: Layoffs Hit Elan 01/26/11 San Francisco
Biogen Aims to Reduce PML Risk 12/22/10 Boston
Biogen Idec Buys Drug Rights from Neurimmune for $32.5M 12/21/10 Boston
Biogen Idec Chief Aims to Make Firm More Like Biotech and Less Like Pharma with Restructuring Plan 11/04/10 Boston
Biogen Idec Offering Jobs to Quarter of San Diego Workers, While Most Get Layoff Notices 11/03/10 Boston
Biogen Idec Axes 650 Jobs, Closes San Diego Site, Bets Future on Neurology 11/03/10 Boston
Biogen Rival Reaches Finish Line with Oral Drug for MS 09/22/10 Boston
Arena Signs Deal With Eisai for Lorcaserin, Qualcomm CEO Identifies Two Opportunities in Mobile Health, & More San Diego Life Sciences News 07/08/10 San Diego
New CEO George Scangos Says Biogen Idec’s R&D Has to Improve 07/01/10 Boston
Chairman Bill Young: Next Biogen Idec CEO May Be a Scientist 02/22/10 Boston
Tysabri’s PML Count Climbs to 28, and Some Reflections From Biogen Idec’s Departing CEO 01/06/10 Boston
Biogen Idec CEO Jim Mullen Stepping Down, After Tumultuous Year of Shareholder Activism 01/04/10 Boston
Facet Rejects Biogen’s Latest Offer 12/10/09 Boston
Biogen Fattens Offer to Buy Facet Biotech 12/03/09 Boston
Biogen Idec Accused Again of Excessive CEO Pay, Lousy Performance, By Big Shareholder 11/20/09 Boston
Tysabri, the MS Drug Haunted by Deadly Side Effect, Doesn’t Look So Deadly Anymore 11/19/09 Boston
Biogen Shares Drop as Tysabri PML Cases Climb to 23, Europe May Seek Drug ‘Holiday’ 10/23/09 Boston
Tysabri’s Tally of PML Cases Reaches 13 09/17/09 Boston
Elan Breached Tysabri Partnership With Biogen Idec, Federal Judge Says 09/04/09 Boston
Biogen Idec Faces Suit From Partner Elan, Genzyme Wins European Approval for Stem-Cell Boosting Drug, Alnylam Teams with Tekmira, & More Boston-Area Life Sciences News 08/12/09 Boston
Elan Hits Biogen Idec with Lawsuit to Protect Tysabri Deal with J&J 08/06/09 Boston
Biogen Gets Int’l Rights to Acorda’s MS Drug 07/01/09 Boston
Page 1 of 3 next page »

Xconomy Events Across the Network

The Napa Summit 2013: New Rules for Growth

San Francisco · 6/3/13

More Xconomy Events

Xconomy’s Most Popular

  1. Henri Termeer on Startups, Drug Prices, Getting Older (Part 1)
  2. Nine Lessons for Innovators from a Nobel Prize-Winning Psychologist
  3. Xconomy Opens in Texas, Expanding Roundup of Innovation Across U.S.
  4. Life After PowerPoint: Prezi Zooms Ahead in Digital Storytelling
  5. Zillions of Biotech Conferences Want You. Which Should You Attend?

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now
IDG Tech Network
Protected by Mozy
Eventbrite - events made easy

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York, Boulder/Denver, Texas and beyond.

© 2007-2013, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Website development support from Andrew Koyfman with design support from Rob Hunter.